Paper41598653
Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study.
Morel O and 8 others. J Clin Med, 2026. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study. Papers, record 41598653. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41598653
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Assessing Potential Valve-Preserving Effects of SGLT2 Inhibitors in Degenerative Aortic Stenosis: A Propensity-Matched Study.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References19
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39739876 | SGLT2 expression in human vasculature and heart correlates with low-grade inflammation and causes eNOS-NO/ROS imbalance. | Cardiovasc Res | 2025 | https://conductscience.org/library/papers/39739876 | PubMed |
| 2 | 39170957 | Human Aortic Stenotic Valve-Derived Extracellular Vesicles Induce Endothelial Dysfunction and Thrombogenicity Through AT1R/NADPH Oxidases/SGLT2 Pro-Oxidant Pathway. | JACC Basic Transl Sci | 2024 | https://conductscience.org/library/papers/39170957 | PubMed |
| 3 | 39565463 | Could SGLT2 inhibitors improve outcomes in patients with heart failure and significant valvular heart disease? Need for action. | Heart Fail Rev | 2025 | https://conductscience.org/library/papers/39565463 | PubMed |
| 4 | 39613203 | Risk of death and thrombosis in patients admitted to the emergency department with supraventricular tachycardias. | Heart Rhythm | 2025 | https://conductscience.org/library/papers/39613203 | PubMed |
| 5 | 41232829 | Impact of SGLT2 inhibitors on long-term outcomes in TAVI patients with heart failure: a propensity-matched analysis. | Rev Esp Cardiol (Engl Ed) | 2026 | https://conductscience.org/library/papers/41232829 | PubMed |
| 6 | 33478648 | The Pleiotropic Effects of SGLT2 Inhibitors: Remodeling the Treatment of Heart Failure. | J Am Coll Cardiol | 2021 | https://conductscience.org/library/papers/33478648 | PubMed |
| 7 | 40286382 | The Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Bioprosthetic Aortic Valve Degeneration. | JACC Adv | 2025 | https://conductscience.org/library/papers/40286382 | PubMed |
| 8 | 41294140 | Detrimental Effect of Plasma From Patients With Severe Aortic Stenosis on Valvular Endothelial Cells: Role of Proinflammatory Cytokines and Factor Xa. | J Am Heart Assoc | 2026 | https://conductscience.org/library/papers/41294140 | PubMed |
| 9 | 41096081 | Association of SGLT2 Inhibitors with Mortality and Bioprosthesis Valve Failure After TAVR: A Propensity-Matched Cohort Study. | J Clin Med | 2025 | https://conductscience.org/library/papers/41096081 | PubMed |
| 10 | 39985508 | Effect of Sodium-Glucose Cotransporter-2 Inhibitors on the Progression of Aortic Stenosis. | JACC Cardiovasc Interv | 2025 | https://conductscience.org/library/papers/39985508 | PubMed |
| 11 | 39930557 | GLP-1 receptor agonists and cardiovascular events in metabolically healthy or unhealthy obesity. | Diabetes Obes Metab | 2025 | https://conductscience.org/library/papers/39930557 | PubMed |
| 12 | 41392217 | Dapagliflozin inhibits TGF-β-induced transdifferentiation of valvular interstitial cells and mitral valvular degeneration. | J Mol Med (Berl) | 2025 | https://conductscience.org/library/papers/41392217 | PubMed |
| 13 | 38247224 | Myocardial sodium-glucose cotransporter 2 expression and cardiac remodelling in patients with severe aortic stenosis: The BIO-AS study. | Eur J Heart Fail | 2024 | https://conductscience.org/library/papers/38247224 | PubMed |
| 14 | 40908107 | Vascular effects of SGLT2 inhibitors: evidence and mechanisms. | Am J Physiol Cell Physiol | 2025 | https://conductscience.org/library/papers/40908107 | PubMed |
| 15 | 40162639 | Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40162639 | PubMed |
| 16 | 37373620 | Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. | J Clin Med | 2023 | https://conductscience.org/library/papers/37373620 | PubMed |
| 17 | 35981841 | Impact of Moderate Aortic Stenosis on Long-Term Clinical Outcomes: A Systematic Review and Meta-Analysis. | JACC Cardiovasc Interv | 2022 | https://conductscience.org/library/papers/35981841 | PubMed |
| 18 | 37344038 | Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. | J Am Coll Cardiol | 2023 | https://conductscience.org/library/papers/37344038 | PubMed |
| 19 | 36537038 | Aortic stenosis and the haemostatic system. | Cardiovasc Res | 2023 | https://conductscience.org/library/papers/36537038 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42919410 | SGLT2 inhibitor therapy following aortic valve intervention for aortic stenosis: a systematic review and meta-analysis of mortality, heart failure, rhythm, renal, and valve-related outcomes. | J Cardiothorac Surg | 2026 | https://conductscience.org/library/papers/42919410 | PubMed |
| 42769931 | Sodium-Glucose Cotransporter-2 Inhibitors in Valvular Heart Disease: From Mechanistic Insights to Clinical Application. | J Soc Cardiovasc Angiogr Interv | 2026 | https://conductscience.org/library/papers/42769931 | PubMed |
| 42652758 | Sodium-Glucose Cotransporter 2 Inhibitors in Valvular Heart Disease: Cardiovascular Benefit, Valve-Specific Effects, and Evidence Gaps-A Structured Narrative Review. | J Clin Med | 2026 | https://conductscience.org/library/papers/42652758 | PubMed |
| 42233563 | SGLT2 Inhibition as a Novel Therapeutic Strategy in Rheumatic Heart Disease. | JACC Asia | 2026 | https://conductscience.org/library/papers/42233563 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| SLC5A2 | 6524 | PubTator's text mining | https://conductscience.org/library/genes/6524 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41598653
GET https://conductscience.org/api/papers/v1/41598653/authors